How many prefaces do I need to give to make it clear it was not a direct comparison? As said above, there are obvious trial differences, not least one is phase III and one in phase I for a start. It was a yardstick comparison in the most obvious comparator.
And yes I am well aware of the differences in GvHD across the two cohorts:
Amongst a number of reasons MSB doing pediatric is the lack of an approved GVHD therapy in under 12's (who don’t respond to steroid therapies). That's a misnomer in itself as we all know Ruxolitinib (Jakafi) for adults is crap too and Remestemcel-L offers hope there too. Pediatrics is arguably an easier win and morally more pressing need for MSB.
Correct me if I am wrong but I'd have to go back to the 2006 trial results to compare MSB last adult GVHD adult trial (even though MSB's related clinicians' were less informed on GvHD, MOA's, etc)? Its pre-Osiris technology, and a host of other factors that make it an even less desirable yardstick.
Regards your other questions, suggest read the release and trial details. And yes I know there are some 80 other Mesenchymal trials going on in GvHD, but clearly MSB the go to comparison for investors after the acrimonious back and forth on here over the years.
CYP Price at posting:
15.0¢ Sentiment: Buy Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)